Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T13:45:32.871Z.
Calculation as of: 2026-10-06T13:45:32.871Z.
Quote observation: 2026-10-06T13:45:02.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 0fde8dae4c5ae63ee7b35c7e6e46bba2fdf5d6d5db310b32cf0eb41a7e17e840
PE RATIO
N/A
Market Cap
$848.19M
PE Ratio
N/A
TTM Avg
76.88
3Y Avg
76.88
5Y Avg
76.88
Market Cap
$891.36M
PE Ratio
N/A
TTM Avg
43.56
3Y Avg
43.56
5Y Avg
43.56
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Apnimed, Inc. (APMD) | $847.84M | N/A | N/A | N/A | N/A |
| Jade Biosciences, Inc. (JBIO)vs › | $852.65M | N/A | N/A | N/A | N/A |
| Monte Rosa Therapeutics, Inc. (GLUE)vs › | $848.19M | N/A | 76.88 | 76.88 | 76.88 |
| Beta Bionics, Inc. (BBNX)vs › | $857.50M | N/A | N/A | N/A | N/A |
| Alumis Inc. (ALMS)vs › | $837.98M | N/A | N/A | N/A | N/A |
| Ardelyx, Inc. (ARDX)vs › | $823.84M | N/A | 197.34 | 197.34 | 197.34 |
| Corvus Pharmaceuticals, Inc. (CRVS)vs › | $891.36M | N/A | 43.56 | 43.56 | 43.56 |
| InMode Ltd. (INMD)vs › | $813.07M | 11.50 | 9.51 | 9.54 | 15.29 |
| Arbutus Biopharma Corp (ABUS)vs › | $905.71M | 5.87 | 5.80 | 5.80 | 5.80 |
| Gyre Therapeutics, Inc. (GYRE)vs › | $804.39M | N/A | 694.69 | 438.87 | 438.87 |
Trailing P/E
N/A
Forward P/E
N/A
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
